SLC6A5 Gene

SLC6A5 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A5 Gene</th>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Therapeutic Rationale</td>
</tr>
<tr>
<td class="label">Schizophrenia</td>
<td>GlyT1 inhibition increases glycine for NMDA co-agonism</td>
</tr>
<tr>
<td class="label">Stroke/TBI</td>
<td>GlyT1 inhibition reduces excitotoxicity</td>
</tr>
<tr>
<td class="label">Hyperekplexia</td>
<td>Gene therapy to restore transport</td>
</tr>
<tr>
<td class="label">ADHD</td>
<td>GlyT1 modulators for prefrontal function</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

SLC6A5 encodes Glycine Transporter 1 (GlyT1), a sodium/chloride-dependent glycine transporter primarily expressed in astrocytes and endothelial cells of the blood-brain barrier. GlyT1 plays a critical role in terminating glycinergic neurotransmission, maintaining extracellular glycine concentrations, and regulating the balance between excitatory and inhibitory signaling in the central nervous system[@broer2021][@kristensen2011].

SLC6A5 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A5 Gene</th>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Therapeutic Rationale</td>
</tr>
<tr>
<td class="label">Schizophrenia</td>
<td>GlyT1 inhibition increases glycine for NMDA co-agonism</td>
</tr>
<tr>
<td class="label">Stroke/TBI</td>
<td>GlyT1 inhibition reduces excitotoxicity</td>
</tr>
<tr>
<td class="label">Hyperekplexia</td>
<td>Gene therapy to restore transport</td>
</tr>
<tr>
<td class="label">ADHD</td>
<td>GlyT1 modulators for prefrontal function</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

SLC6A5 encodes Glycine Transporter 1 (GlyT1), a sodium/chloride-dependent glycine transporter primarily expressed in astrocytes and endothelial cells of the blood-brain barrier. GlyT1 plays a critical role in terminating glycinergic neurotransmission, maintaining extracellular glycine concentrations, and regulating the balance between excitatory and inhibitory signaling in the central nervous system[@broer2021][@kristensen2011].

The SLC6A5 locus is on chromosome 11p15.5 and encodes a 12-transmembrane-domain protein of approximately 635 amino acids. GlyT1 is distinct from GlyT2 (SLC6A9) in its ionic coupling (Na+/Cl- dependence), tissue distribution, and physiologic function. While GlyT2 is primarily presynaptic and mediates glycine reuptake at inhibitory synapses, GlyT1 is largely extrasynaptic and controls ambient extracellular glycine levels that modulate both glycinergic and NMDA receptor-mediated glutamatergic signaling[@zafra2017].

Gene And Protein Architecture

SLC6A5 encodes a prototypical SLC6 family member with the canonical 12-transmembrane helix topology:

• N-terminal intracellular domain: Contains regulatory motifs for protein kinase C (PKC) phosphorylation and interaction with scaffolding proteins.
• Transmembrane core: Forms the substrate-binding pocket (S1 site) and the gated external vestibule. The transporter alternates between outward-facing and inward-facing conformations during the transport cycle.
• Extracellular loops: Highly glycosylated, with N-linked glycosylation sites essential for proper folding and surface expression.
• C-terminal intracellular tail: Contains a PDZ-binding motif for interaction with synaptic scaffolding proteins and determines subcellular localization.

Transport Mechanism

GlyT1 operates via an alternating access mechanism coupling glycine transport to the electrochemical gradients of Na+ and Cl-:

This transport cycle is electrogenic (net +1 charge per glycine molecule) and can be modulated by multiple regulatory inputs including phosphorylation, glycosylation, and protein-protein interactions[@biche2023].

Physiologic Role In The CNS

Glycinergic Synaptic Transmission

GlyT1 is essential for clearing glycine from the synaptic cleft following glycinergic neurotransmission. At brainstem and spinal cord inhibitory synapses, GlyT1 (primarily the GlyT2 isoform in presynaptic terminals) terminates synaptic signaling by reuptake. However, GlyT1's role is distinct: it maintains ambient extracellular glycine levels that influence:

• Glycinergic tone: Steady-state glycine concentrations at glycine receptors
• NMDA receptor modulation: Glycine is a co-agonist at NMDA-type glutamate receptors; GlyT1 indirectly regulates glutamatergic excitotoxicity through glycine availability
• Excitatory-inhibitory balance: By controlling extracellular glycine, GlyT1 modulates the gain of NMDA-mediated excitatory transmission

Astrocytic Function

Astrocytic GlyT1 is strategically positioned to:

• Monitor and regulate extracellular glycine across gray matter
• Provide glycine for neuronal uptake when needed for neurotransmitter synthesis
• Participate in the astrocyte-neuron lactate shuttle and metabolic coupling
• Respond to neuronal activity with rapid transporter trafficking

Blood-Brain Barrier Expression

A distinctive feature of GlyT1 is its expression in brain microvascular endothelial cells forming the blood-brain barrier (BBB). Here, GlyT1 mediates glycine transport across the BBB and contributes to the selective permeability of amino acid neurotransmitters. This has therapeutic implications for drug delivery targeting glycineergic systems.

SLC6A5 In Neurodegeneration

Hyperekplexia (Startle Disease)

Hyperekplexia, also known as startle disease or stiff baby syndrome, is a rare neurodevelopmental disorder characterized by exaggerated startle responses, hypertonia in infancy, and episodic falling. SLC6A5 is one of several genes (along with GLRA1, GLRB, and SLC6A9) where pathogenic variants cause hyperekplexia[@hirano2020][@raas2021].

Mechanistic basis:

• Loss-of-function variants reduce GlyT1-mediated glycine reuptake
• Elevated extracellular glycine causes excessive glycinergic inhibition
• Brainstem circuitry mediating startle reflex becomes hyperexcitable
• Motor neurons receive excessive inhibitory input, causing tonic rigidity

• Missense variants often cause milder phenotypes with later onset
• Truncating variants typically cause severe neonatal-onset disease
• Compound heterozygosity can produce intermediate phenotypes

Epilepsy

SLC6A5 variants are associated with early-onset epilepsy, particularly in patients with comorbid hyperekplexia. The mechanistic link involves disrupted glycinergic inhibition during critical developmental periods, leading to hyperexcitability and seizure susceptibility. Animal models show that GlyT1 knockout produces spontaneous seizures and early mortality[@biche2023].

NMDA Receptor Dysregulation

By controlling extracellular glycine levels, GlyT1 indirectly regulates NMDA receptor activity. This connection is relevant to:

• Excitotoxicity: Excessive glycine can over-activate NMDA receptors, contributing to excitotoxic cell death in conditions like stroke and traumatic brain injury.
• Schizophrenia: Reduced GlyT1 function may contribute to NMDA receptor hypofunction theory of schizophrenia; GlyT1 inhibitors have been explored as antipsychotic agents.
• Neurodegenerative processes: Chronic dysregulation of glycine-mediated excitotoxicity may contribute to progressive neurodegenerative conditions.

Therapeutic Implications

GlyT1 is a therapeutic target in multiple CNS disorders:

Clinical Genetics

Variant Spectrum

SLC6A5 pathogenic variants include:

• Missense variants: Predominantly affect transmembrane domains and substrate-binding sites
• Splicing variants: Cause exon skipping or intron retention
• Frameshift/nonsense variants: Produce truncated non-functional proteins
• Copy number variants: Rare but documented

Inheritance Pattern

SLC6A5-associated hyperekplexia follows autosomal recessive inheritance, consistent with the requirement for biallelic loss-of-function to produce the phenotype. Heterozygous carriers are typically asymptomatic but may show subtle endophenotypes.

Population Genetics

SLC6A5 shows constraint against loss-of-function variation. The gene has a low pLI score and elevated missense Z-score, indicating evolutionary constraint on functional disruption.

Structural Biology

SLC6 Family Architecture

GlyT1 shares structural homology with other SLC6 family members including:

• GABA transporters (GAT1/SLC6A1, GAT3/SLC6A13)
• Dopamine transporter (DAT/SLC6A3)
• Serotonin transporter (SERT/SLC6A4)

• S1 substrate-binding site: Deep within the transmembrane core
• S2 allosteric site: Extracellular vestibule, target for competitive inhibitors
• Ionic binding sites: Conserved Na1 and Na2 sites for sodium coupling
• Conformational states: Outward-facing, occluded, and inward-facing conformations captured

Inhibitor Binding

Several GlyT1 inhibitor classes have been developed:

• Sarcosine derivatives: Early competition-based inhibitors
• NFPS (N-[3-(4'-fluorophenyl)-3-(4'-phenyl)phenoxy]propyl]sarcosine): Selective GlyT1 inhibitor
• Bitopertin (RG1678): Clinical candidate for schizophrenia (failed Phase III)
• SPF-PCA (serine-derived): Novel allosteric modulators

Research Models

Animal Models

• GlyT1 knockout mice: Neonatal lethality, severe phenotype
• Conditional knockouts: Region-specific deletion reveals circuit-specific functions
• Humanized models: Transgenic expression of patient variants

In Vitro Systems

• HEK293 expression: Standard for variant functional characterization
• Xenopus oocytes: Electrophysiological transport assays
• iPSC-derived neurons: Patient-specific disease modeling

Biomarker And Clinical Relevance

Diagnostic Testing

SLC6A5 sequencing is included in hyperekplexia gene panels. Diagnostic yield is approximately 5-10% of clinically diagnosed hyperekplexia cases, with GLRA1 being the more commonly mutated gene.

Functional Assays

• Radiolabeled glycine uptake: Measures transport function in patient fibroblasts
• Surface expression assays: Flow cytometry for trafficking-defective variants
• Electrophysiology: Voltage-clamp measurement of glycine-induced currents

Therapeutic Development

Challenges

The GlyT1 field has faced significant translational challenges:

• Bitopertin Phase III failure: Despite preclinical promise, GlyT1 inhibition failed to show efficacy in schizophrenia
• Peripheral toxicity: Systemic GlyT1 inhibition causes peripheral side effects
• BBB penetration: Achieving sufficient CNS exposure without peripheral effects

Future Directions

• Allosteric modulators: Target S2 site with subtype selectivity
• Gene therapy: AAV-mediated delivery to restore transport function
• Antisense oligonucleotides: Allele-specific silencing for dominant-negative variants
• Targeted protein degradation: Induced degradation of mutant protein

Summary

SLC6A5 encodes GlyT1, the sodium/chloride-dependent glycine transporter essential for glycinergic neurotransmission and NMDA receptor co-agonism. The gene is primarily associated with hyperekplexia and epilepsy, where loss-of-function variants cause excessive glycinergic inhibition and network hyperexcitability. GlyT1's expression in astrocytes and blood-brain barrier endothelial cells makes it a unique therapeutic target at the intersection of inhibitory and excitatory neurotransmission.

Key aspects for neurodegeneration research include:

See Also

• [SLC6A9 Gene](/genes/slc6a9) - GlyT2, the presynaptic glycine transporter
• [Hyperekplexia](/diseases/hyperekplexia)
• [Epilepsy](/diseases/epilepsy)
• [Astrocytes](/entities/astrocytes)
• [Glycinergic Neurotransmission](/mechanisms/glycinergic-neurotransmission)
• [NMDA Receptor Signaling](/mechanisms/nmda-receptor-signaling)

External Links

• [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/6402)
• [OMIM](https://www.omim.org/entry/604159)
• [UniProt](https://www.uniprot.org/uniprot/O43576)
• [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145979)

Allen Brain Atlas

• [Human Brain Map - SLC6A5 Expression](https://human.brain-map.org/microarray/search/show?search_term=SLC6A5)
• [BrainSpan Transcriptome Atlas](https://brainspan.org/)

References